Selecting one or more of the options below will update the content below.

Show / Hide Filters
Age Group
Type of Study
Study Format
Location
Target Population
  • Clinical Trial
    In-Person

    What is this Study about?

    The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 50 months.

    Eligibility Criteria

    Male or female participants aged 50 years of age
    Has a history of previous clinical intracerebral hemorrhage.
    Has probable CAA.

    Recruitment End Date

  • Clinical Trial
    In-Person

    What is this Study about?

    This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.

    Eligibility Criteria

    Male or female participants aged 50 years of age to 90.
    Report of objective or subjective memory concerns (by the participant and/or their informant) within the last year with or without a previous clinical diagnosis of MCI or dementia due to AD.

    Recruitment End Date

  • Clinical Trial
    In-Person

    What is this Study about?

    The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment [MCI] to mild dementia due to AD).

    Eligibility Criteria

    Male or female participants aged 50 years of age to 90.
    Must have a study partner
    Participant- and/or Informant-reported history of cognitive decline with gradual onset and progression over the last 1 year before screening

    Recruitment End Date

  • Clinical Trial
    In-Person

    What is this Study about?

    The purpose of this study is to find out whether treatment with VHB937 is safe and beneficial in people with early Alzheimer's disease. The study will evaluate the safety of VHB937, as well as its effects on memory and other thinking abilities, on daily activities, and on changes in the brain. The study will also observe and measure how VHB937 is processed by the body and how the body responds to it.
    Official Title

    Eligibility Criteria

    Male or female participants aged 50 years of age to 85.
    Must have a study partner
    Diagnosis of Mild Cognitive Impairment (MCI) due to AD or mild AD

    Recruitment End Date

  • Observational Study
    In-Person

    What is this Study about?

    Older adults are at greater risk for experiencing a reduction in cognitive and physical function. It is imperative that we identify health behaviors and non-pharmacological (i.e., non-medication) interventions to mitigate these declines. One promising lifestyle intervention to prevent or delay the onset of such declines is exercise, which has been found to improve cognitive function (mental abilities used to perform simple and complex tasks), physical function (muscle mass, bone density) and brain health (structure and function). There is also research demonstrating that creatine, a naturally occurring compound in the body known to decrease with age, can increase muscle mass and bone density in older adults when supplemented. However, it is unclear what effects creatine may have on cognition and brain health in older adults. Thus, our project will investigate the effects of creatine supplementation on cognition and brain health in older adults when combined with different types of exercise. Given the safety, accessibility and known reduction in creatine levels with age, examining how creatine supplementation may benefit older adults is well worth investigating.

    Eligibility Criteria

    To be eligible to participate in this study you must:

    • be 60 years of age or older

    • be living independently in the community

    • have normal or corrected-to-normal vision and hearing

    • read, write, and speak English fluently

    • have feelings of memory decline in the past 5 years

    • be able to exercise at a moderate pace for 60 minutes 3x/week receive clearance from a medical doctor (once deemed eligible) to participate in an exercise program

    You are ineligible to participate in this study if you:

    • cannot partake or commit to exercise training 3x/week for 26 weeks or have regularly engaged in exercise (more than once per week) over the past 3 months

    • cannot partake or commit to consuming a daily supplement for 26 weeks or consumed nutritional supplements containing creatine monohydrate over the past 3 months

    • have a known allergy to creatine monohydrate or dextrose (glucose, D-glucose)

    • have been diagnosed with a neurological disorder (e.g., Alzheimer’s disease, Parkinson’s disease)

    • have pre-existing kidney disease, heart disease, or liver abnormalities

    • have one or more uncontrolled chronic or psychiatric conditions (e.g., hypertension, diabetes, depression, anxiety)

    • are taking medication that may impact kidney function (e.g., non-steroidal anti-inflammatory drugs, such as ibuprofen and naproxen)

    • are ineligible or uncomfortable with blood sampling.

    Recruitment End Date

  • Observational Study
    In-Person

    What is this Study about?

    McMaster University is conducting a study on the effects of brain stimulation in individuals aged 50 and older with dementia or memory loss. The research focuses on using repetitive transcranial magnetic stimulation (rTMS), a noninvasive technique that delivers magnetic pulses to the brain, to enhance cognitive function and balance. The goal is to extend the positive effects of brain stimulation in improving cognition and balance in individuals with dementia.

    Eligibility Criteria

    1.) Diagnosed with Dementia and/or memory loss by a clinician

    2.) Exhibit adequate oral communication skills and cognitive function

    3.) Walk or stand with or without personnel or assistive devices

    4.) Individuals must be greater than or equal to 50 years of age

    Recruitment End Date

  • Observational Study
    In-Person

    What is this Study about?

    Compass-ND is a research study designed to assess individuals with different sorts of cognitive and movement changes seen in older adults. We will look at the usefulness of imaging studies, clinical assessments and biomarker tests, together with measurements of memory, thinking and daily functioning, for distinguishing these changes from each other and from healthy aging.

    Eligibility Criteria

    - are between the ages 60-90

    - have up to grade 12 education

    - have an individual (spouse, friend, or relative), called a “study partner,” who is willing to:

    - Accompany you to the study visits

    - Communicate to the study staff of changes in your health status over the period of this study

    Recruitment End Date

  • Observational Study
    In person & Online

    What is this Study about?

    This study explores how adult day programs affect the lives of people living with dementia and their caregivers across several Canadian regions. Over time, we gather information about health, well-being, daily experiences, and quality of life of people living with dementia who attend day program and their caregivers. We also aim to learn about day programs themselves, such as their activities, staffing, challenges, and successes. By combining surveys, interviews, and focus groups, our program of research aims to understand what makes day programs helpful, where challenges exist, and how day program can better support families, and people who use them.

    Eligibility Criteria

    You are eligible to participate if you:

    • Are an older adult living with dementia who attends or does not attend a day program

    • You are a family/friend caregiver of someone living with dementia who attends or does not attend a day program

    • Live in one of the participating regions (Ontario, Winnipeg MB, Calgary AB, or Interior BC)

    • Are able to take part in a conversation or complete surveys, with support if needed

    Recruitment End Date

  • Observational Study
    In-Person

    What is this Study about?

    Hearing loss is the third most common chronic health condition among people 65 and older and increases the risk of social isolation, depression, communication difficulties and dementia. Dementia risk may be reduced through hearing rehabilitation, and it is critical to develop tools for identifying hearing loss and its impact on communication. The Hearing and Functioning in Everyday Life Questionnaire (HFEQ) is a measure to identify hearing loss and everyday life functioning, not yet been evaluated for people with combined hearing loss and cognitive impairment. To bridge this gap, the aim is to evaluate the HFEQ for this group. The study has a cross-sectional observational study design. Adults over 60 years, with hearing loss and with and without cognitive impairment will be recruited. Data collection will include a cognitive and hearing assessment, assessment of conversation effectiveness and efficiency, hearing and general health history and five questionnaires (HFEQ, the Life-Space questionnaire, the Social Functioning in Dementia scale, and the PROMIS anxiety and depression scales).

    Eligibility Criteria

    • Are 60 years or older

    • Have hearing loss

    Experience cognitive complaints (subjective memory complaints, mild cognitive impairment, or dementia) or,

    • Experience no changes in cognitive function

    Recruitment End Date